Vaseem Mahboob Sells 5,391 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 5,391 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.80, for a total value of $128,305.80. Following the completion of the sale, the chief financial officer owned 93,891 shares of the company’s stock, valued at $2,234,605.80. This trade represents a 5.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies stock traded up $1.16 during midday trading on Monday, hitting $23.99. The company’s stock had a trading volume of 373,728 shares, compared to its average volume of 404,856. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The company has a 50-day moving average price of $22.62 and a two-hundred day moving average price of $22.48.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. As a group, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BTIG Research raised their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. The Goldman Sachs Group cut their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average target price of $27.83.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds have recently added to or reduced their stakes in KMTS. Millennium Management LLC bought a new stake in shares of Kestra Medical Technologies during the first quarter worth $11,036,000. Woodline Partners LP bought a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $2,510,000. Jane Street Group LLC bought a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $756,000. Geode Capital Management LLC grew its position in Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after acquiring an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Kestra Medical Technologies in the 2nd quarter worth about $256,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.